—
C+
C+ The full Closelook — membership. Open the C+ overview

Gilead Sciences Inc (GILD) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Gilead Sciences Inc

GILD in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Gilead Sciences develops and sells medicines, mainly HIV treatments such as Biktarvy and Descovy, alongside hepatitis therapies, CAR T-cell cancer treatments including Yescarta and Tecartus, and the antiviral Veklury used against COVID-19. It runs research partnerships with several biotech firms to widen its pipeline in oncology and immunology. The company is headquartered in Foster City, California.
Where it sits in the stack
Gilead sits outside the AI build-out stack; it belongs to the Healthcare sector of our universe, in the Drug Manufacturers - General sleeve, where the diary tracks pharmaceutical earnings rather than any layer of the compute chain.
Who it is priced against
The diary has no set peer group for Gilead in our records; the comparison the market most often draws is with Bristol-Myers Squibb.
Why Closelook tracks it
Gilead is a Nasdaq-100 constituent but carries no Closelook score at present, and the diary has not yet quoted it in its editions.
What the diary watches
Whether new drug approvals or generic competition in its HIV franchise change the balance between its core treatments and its newer cancer and hepatitis lines.

Gilead Sciences Inc (GILD) trades on US exchanges.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: GILD news on the tape · index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for GILD, from the same nightly bakes the boards use. Research diary readings, not advice.

Who it is priced against Drug Manufacturers - General · US · 8 names with week and year-to-date

Peer group

Drug Manufacturers - General · US

This name carries no Closelook score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against GILD on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Dividends and capital return trailing yield 2.15%, quarterly · last 0.82 USD on 2026-09-15

Dividends and capital return

What GILD pays out and buys back — distributions read from the price series, money terms from the filings.

  • Trailing 12 months 3.25 USD per share · a 2.15% yield on the 2026-09-17 close 4 distributions, paid quarterly 2026-09-17
  • Change on the year +3.5% against the prior twelve months prior twelve months 3.14 USD per share
  • Last distribution 0.82 USD per share as the price series records it, within days of the ex-date 2026-09-15
  • By calendar year 2023: 0.75 USD (partial) · 2024: 3.08 USD · 2025: 3.16 USD · 2026: 2.46 USD to date first distribution recorded in the three-year window: 2023-12-14

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 55/100 · S&P 500 fund at 58, above its 50- and 200-day averagesEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-17
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 94th percentile of the window, +2.7% over 20 sessions. Factor regime → 2026-09-17
  • Sovereign pressure Index 0.00 · down 0.41 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-17

FAQ · from the current data · as of 2026-09-18

Quick answers

What is Gilead Sciences Inc (GILD)?

Gilead Sciences Inc trades as GILD on the US exchange (US) in the Closelook research universe, as of the registry build of 2026-09-18.

Is GILD in a Closelook index?

Not currently — Gilead Sciences Inc is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-18.

Where does GILD trade against its moving averages?

Uptrend stack intact: Trades +8.4% vs the 50-day and +11.9% vs the 200-day average, 3.5% below the 52-week high and +40.8% off the 52-week low; a golden cross printed 16 sessions ago. Computed from daily closes. As of 2026-09-17 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does Gilead Sciences Inc do?

Gilead Sciences develops and sells medicines, mainly HIV treatments such as Biktarvy and Descovy, alongside hepatitis therapies, CAR T-cell cancer treatments including Yescarta and Tecartus, and the antiviral Veklury used against COVID-19. It runs research partnerships with several biotech firms to widen its pipeline in oncology and immunology. The company is headquartered in Foster City, California. The diary has no set peer group for Gilead in our records; the comparison the market most often draws is with Bristol-Myers Squibb.

Where does Gilead Sciences Inc sit in the AI build-out?

Gilead sits outside the AI build-out stack; it belongs to the Healthcare sector of our universe, in the Drug Manufacturers - General sleeve, where the diary tracks pharmaceutical earnings rather than any layer of the compute chain. Gilead is a Nasdaq-100 constituent but carries no Closelook score at present, and the diary has not yet quoted it in its editions.

Does Gilead Sciences Inc pay a dividend?

Gilead Sciences Inc has paid 3.25 USD per share over the last twelve months, paid quarterly, a trailing yield of 2.15% on the 2026-09-17 close; the last distribution recorded in the price series was 0.82 USD on 2026-09-15. The "Dividends and capital return" block on this page carries the lines.

What does this page show?

A live price chart with SMA overlays and drawing tools for GILD, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe

then Drug Manufacturers - General, then Healthcare. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.